

James A Underberg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5561730/james-a-underberg-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

1,188
citations

16
h-index

34
g-index

59
ext. papers

1,464
ext. citations

4.2
avg, IF

3.99
L-index

#	Paper	IF	Citations
48	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015 , 9, S1-122.e1	4.9	293
47	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). <i>Circulation</i> , 2013 , 127, 1052-89	16.7	111
46	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). <i>Circulation</i> , 2013 , 127, 1052-89	15.1	81
45	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 880-890	4.9	73
44	Rationale and design of the familial hypercholesterolemia foundation CASCADE SCReening for Awareness and DEtection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014 , 167, 342-349.e17	4.9	63
43	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016 , 165, 867-868	8	61
42	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017 , 40, 243-254	3.3	52
41	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease). <i>Circulation</i> , 2009 , 120, e100-26	15.1	44
40	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017 , 267, 19-26	3.1	36
39	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019 , 289, 85-93	3.1	35
38	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 398-413	4.9	29
37	Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 465-79	3.9	28
36	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 273-82	4.9	27
35	Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 390-6	3.1	26
34	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 450-458.e1	4.9	21
33	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease). <i>Circulation</i> , 2009 , 120, e100-26	16.7	21
32	Cardiovascular Effects of the New Weight Loss Agents. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 849-59	15.1	16

31	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 573-609	4.9	16
30	2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease	1.3	14
29	Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management. <i>Current Diabetes Reports</i> , 2011 , 11, 64-9	5.6	14
28	Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). <i>Journal of Clinical Lipidology</i> , 2020 , 14, 807-817	4.9	14
27	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021 , 319, 51-61	3.1	12
26	Laparoscopic gastric banding resolves the metabolic syndrome and improves lipid profile over five years in obese patients with body mass index 30-40 kg/m(2.). <i>Atherosclerosis</i> , 2014 , 237, 183-90	3.1	11
25	The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 48	6	10
24	Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1177-1180	4.9	9
23	Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease. <i>Cardiology</i> , 2019 , 142, 83-90	1.6	8
22	Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. <i>American Heart Journal</i> , 2014 , 168, 310-316.e3	4.9	8
21	Characterization of PCSK9 in the Blood and Skin of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 308-315	4.3	8
20	The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 494	6	7
19	Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 603-9	7.5	6
18	Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?. <i>Urologic Clinics of North America</i> , 2016 , 43, 247-60	2.9	5
17	JCL roundtable: Risk evaluation and mitigation strategy. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1288-1296	4.9	5
16	Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. <i>American Heart Journal</i> , 2018 , 199, 37-43	4.9	4
15	LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). <i>Journal of the American College of Cardiology</i> , 2018 , 71, A168	15.1	4
14	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , 2016 , 128 Suppl 1, 31-9	3.7	4

13	Genetic effects on efficacy of lipid-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1112-1117	4.9	2
12	The role of mipomersen therapy in the treatment of familial hypercholesterolemia. <i>Clinical Investigation</i> , 2012 , 2, 1033-1037		2
11	Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 290-296	6.1	1
10	JCL Roundtable: Global Think Tank on Lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2021 , 15, 387-393	4.9	1
9	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.. <i>Journal of the American Heart Association</i> , 2022 , e024176	6	0
8	Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014 , 399-413	0	
7	Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics. <i>American Journal of Medicine</i> , 2017 , 130, 1233 ^{2,4}		
6	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1300-1308		
5	The National Lipid Association's new recommendations for patient-centered management of cholesterol. <i>Clinical Lipidology</i> , 2015 , 10, 13-15		
4	Relationship between plasma apolipoprotein B concentrations and LDL particle number. <i>Research Reports in Clinical Cardiology</i> , 2014 , 237	0.1	
3	New Treatment Approaches for Dyslipidemia and its Management. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 395-400	0.9	
2	Utility of different lipid measures to predict coronary heart disease. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 35-6; author reply 36	27.4	
1	Bridging the gap in treatment options for patients with hypertriglyceridemia. <i>Journal of Family Practice</i> , 2007 , 56, S24-31	0.2	